Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial

RCT (305) found patients assigned to intensification of full basal-bolus insulin (BBI) or fixed ratio of basal insulin plus GLP-1 receptor agonist or combination of basal insulin plus SGLT2 inhibitor experienced similar reduction in HbA1c at 6 months (−0.6%, −0.6%, and −0.7%).

Source:

Diabetes Care